Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer

Table 4 Correlations between overall survival and various clinicopathological factors

	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Performance status (≥ 1)	3.821	1.805-8.087	< 0.001	3.345	1.558-7.182	0.002
Location of primary tumor (colon)	1.405	0.857-2.304	0.177
Detection of unresectable tumor (synchronous)	1.407	0.852-2.312	0.182
Histological type (poorly, mucinous)	1.283	0.644-2.556	0.478
Peritoneal dissemination (yes)	0.981	0.534-1.802	0.951
Number of organs affected by metastasis (≥ 2)	1.637	1.012-2.648	0.045	1.270	0.737-2.187	0.389
Pre-treatment CEA (> 5 ng/mL)	1.949	0.841-4.521	0.120
Resection of primary tumor (no)	1.716	0.948-3.104	0.074	1.736	0.871-3.459	0.117
Molecular targeted therapy (yes)	0.496	0.289-0.853	0.011	0.462	0.263-0.813	0.007
Response to chemotherapy (CR, PR)	0.459	0.264-0.797	0.006	0.432	0.244-0.765	0.004
Pre-treatment LMR (< 3.38)	2.273	1.368-3.777	0.002	1.734	0.942-3.192	0.077
Pre-treatment NLR (< 2.8)	2.578	1.569-4.237	< 0.001	1.734	0.947-3.178	0.075

CEA: Carcinoembryonic antigen; CR: Complete response; PR: Partial response; LMR: Lymphocyte to monocyte ratio; NLR: Neutrophil to lymphocyte ratio.